The Implications of the IPASS Study in Lung Cancer
Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the implication of the IPASS study.
Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the implication of the IPASS study.
Clinical Pearls:
- The IPASS study analyzed the EGFR inhibitor gefitinib compared with standard chemotherapy for patients with advanced lung adenocarcinoma without knowledge of EGFR mutation status
- Results showed that patients with EGFR mutated tumors who were treated with gefitinib demonstrated a 70-fold greater benefit and saw improvements in quality of life compared to patients with wild-type tumors
- The IPASS study was the first that concluded there was a need to identify patients early on with EGFR mutations and ensure that they receive an upfront EGFR tyrosine kinase inhibitor
Recent Videos
Related Content
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024Article
In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
